A Phase 3 interventional study of safusidenib and Placebo in Glioma, Astrocytoma, Grade IV and IDH1-mutant Glioma, sponsored by Nuvation Bio Inc.. Recruiting at 61 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Nuvation Bio Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 851 studies in Glioma with a site in United States — 142 open to participants now, 229 under way, 6 of them phase 3. Glioma · United States.
Among the 851 studies in Glioma with a site in United States, this one is the 9th largest by planned enrollment of the 737 interventional ones that give a count, is one of 35 that started in 2023, is one of 20 in phase 3, reaches primary completion later than 185 of the 228 other live ones, and was the 693rd registered.
1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.
Browse Glioma studies →142 of the 851 studies in Glioma with a site in United States are open now. Recruiting first, the newest first:
Nuvation Bio Inc. · Sites in United States
Ages 18+
Children's Hospital of Philadelphia · Sites in United States
Ages 1–21
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
Neonc Technologies, Inc. · Sites in United States
Ages 5–18
Children's National Research Institute · Sites in United States
Ages 3–25
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
851 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 430 · Phase 2 320 · Phase 3 21 · Phase 4 6
First in 1979; this study’s year is marked. 35 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 365 is above the median of 32 across 1,075 interventional studies indexed under Glioma.
Median enrollment 30 across the 737 interventional studies, 69 across the 77 observational. Of the 564 that completed or were terminated, 203 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
172 of 851 have an industry lead sponsor. The 10 most frequent:
Nuvation Bio Inc. is the lead sponsor of 19 studies on the registry; 6 are open to participants now.
Nuvation Bio Inc. has 3 studies filed under Glioma — fewer than ten, so there is no comparison to draw.
88 of the studies in Glioma with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT07814872Harvard Medical School (HMS and HSDM)A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment | 2026-11 |
| NCT03510208Stanford UniversityPanitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | 2026-11 |
| NCT05094336AmgenA Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) | 2026-11-30 |
Add all 88 to your calendar (.ics) → With an account.
Among the 851 studies in Glioma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.
The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled.
The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.
Part 1 of this study will enroll up to 25 patients that will be randomized 1:1:1:1:1 (5 patients per group) to receive one of the daily oral doses of safusidenib at 125 mg twice a day (BID), 250 mg BID, 500 mg once daily (QD), 375 mg BID, or 500 mg BID. The PK characteristics and safety and initial efficacy data will be assessed in Part 1.
Part 1 was fully enrolled as of 19 Dec 2023 and participants are currently ongoing.
Part 2 will include approximately 300 participants with IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Participants will be randomized (1:1) after their last dose of adjuvant temozolomide to receive either oral safusidenib 250 mg BID or placebo in 28-day continuous cycles. Patients will continue treatment until progression of disease or until other discontinuation criteria are met. The tumor response evaluation will be conducted on a regular basis until progression of disease per Blinded Independent Central Review (BICR), consent withdrawal, or death, whichever occurs first. Long-term survival follow-up will be conducted as well.
Part 3 will include approximately 40 participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma with measurable disease who have undergone surgery as their only treatment and are not in need of immediate chemotherapy or radiotherapy. Participants will receive oral safusidenib 250 mg BID in 28-day continuous cycles until disease progression or another reason for discontinuation occurs.
Key Inclusion Criteria for Part 1:
Key Inclusion Criteria for Part 2 and 3:
Key Inclusion Criteria for Part 2:
Key Inclusion Criteria for Part 3:
Key Exclusion Criteria for Part 1:
Key Exclusion Criteria for Part 2 and 3:
Key Exclusion Criteria for Part 2 1. Participants may not have received any anticancer treatments other than surgery, radiation, concurrent/adjuvant temozolomide, and tumor-treating fields. Tumor-treating fields must be discontinued prior to randomization.
Key Exclusion Criteria for Part 3:
1. Participants may not have received any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) for treatment of glioma, including radiotherapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
safusidenib 125mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
Drug: safusidenib
safusidenib 250mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
Drug: safusidenib
safusidenib 500mg qd administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
Drug: safusidenib
safusidenib 375mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
Drug: safusidenib
safusidenib 500mg bid administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with safusidenib until disease progression or development of other unacceptable toxicity.
Drug: safusidenib
safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment until disease progression or another reason for discontinuation occurs.
Drug: safusidenib
Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
Drug: Placebo
safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment until disease progression or another reason for discontinuation occurs.
Drug: safusidenib
safusidenib administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with agent safusidenib until disease progression or development of other unacceptable toxicity.
Also known as: DS-1001b, AB-218
Placebo administered continuously as dosed single agent orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with placebo until disease progression or another reason for discontinuation occurs.
Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs)
calculate Percentage and numbers of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed by CTCAE 5.0
Time frame: From participants sign ICF to 30 days after last dose,average 2 years
Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0
PFS is defined as the time from randomization to the date of the first documented disease progression assessed by BICR per RANO 2.0 or death (by any cause in the absence of disease progression).
Time frame: From randomization until the date of first documented disease progression, average 2 years
Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0
Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Part 1: Cmax of safusidenib
Peak Plasma Concentration (Cmax)
Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)
Part 1: Tmax of safusidenib
the time for safusidenib to reach Cmax
Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)
Part 1: AUC8h of safusidenib
Area under the plasma concentration curve (AUC) from time 0 to 8 hours
Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)
Part 1 : AUC12h of safusidenib
Area under the plasma concentration curve (AUC) from time 0 to 12 hours
Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)
Part 1: AUC24h [QD only] of safusidenib
Area under the plasma concentration curve (AUC) from time 0 to 24h hours for 500mg qd cohort
Time frame: on Cycle 1 Day 1 and Day 8 (every cycle is 28 days)
Part 1 : Ctrough of safusidenib
Lowest plasma concentration reached after AB-218 administration
Time frame: on Days 2, 3, 4, 6, 8, 9 of Cycle 1 and Day 1 of Cycles 2, 3, 4, 6 and 8 (every cycle is 28 days)
Part 1: Overall Response Rate (ORR) assessed by the investigator
ORR (defined as the proportion of participants with the best overall confirmed response of Complete Response (CR), Partial Response (PR) or Minor Response (MR)\[for RANO-HGG/RANO LGG\] according to the appropriate tumor response criteria) as assessed by the Investigator
Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years
Part 1: Duration of Response (DOR) assessed by the Investigator
DOR, defined as the time from the first documentation of objective response (CR, PR, or MR) to the date of the first documentation of disease progression per RANO-HGG/RANO-LGG as applicable, or death (by any cause in the absence of progression), for participants with confirmed objective response, as assessed by the Investigator
Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years
Part 1: Disease control rate (DCR) assessed by the Investigator
DCR, defined as the proportion of patients with a best overall response of CR, PR, Stable Disease (SD), or Minor Response (MR) per RANO-HGG/RANO-LGG as applicable, as assessed by the Investigator
Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years
Part 1: Progression free survival (PFS) assessed by the Investigator
PFS, defined as the time from the first dose of study drug to the date of the first documented disease progression per RANO-HGG/RANO-LGG as applicable, or death (by any cause in the absence of disease progression), as assessed by the Investigator
Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years
Part1: Time to Response (TTR) assessed by the Investigator.
TTR, the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per RANO-HGG/RANO-LGG as applicable, for participants with confirmed objective response, as assessed by the Investigator.
Time frame: From the first dose of study drug until the date of first documented objective response, average 2 years
Part 1: Overall Survival (OS)
OS, defined as the time from randomization to death from any cause. Participants without death information at the analysis cutoff date will be censored at last date known to be alive.
Time frame: from the first dose of study drug to date of death, average 7 years
Part 2: Overall Survival (OS)
OS, defined as the time from randomization to death from any cause.
Time frame: from randomization to date of death, average 7 years
Part 2: PFS assessed by the Investigator.
PFS, defined as the time from randomization to the date of the first documented disease progression per RANO 2.0, or death (by any cause in the absence of disease progression), as assessed by the Investigator.
Time frame: from randomization until the date of first documented disease progression, average 2 years
Part2: Time to Next Intervention (TTNI) by Investigator assessment
TTNI, defined as the time from randomization to initiation of the first new anticancer therapy, or death due to any cause, whichever comes earlier. Participants who neither initiated new anticancer therapy nor have died at the analysis cutoff date will be censored at the last date known to be alive.
Time frame: From randomization until the date of next treatment, average 2 years
Part2: DCR assessed by BICR and by the Investigator
DCR, defined as the proportion of participants with a best overall response of CR, PR, MR, or SD per RANO 2.0, as assessed by the Investigator and BICR
Time frame: from randomization until the date of first documented disease progression, average 2 years
Part2: ORR
ORR, defined as the proportion of participants with the confirmed best overall response of CR, PR, or MR per RANO 2.0, as assessed by BICR and the Investigator.
Time frame: from randomization until the date of first documented disease progression, average 2 years
Part2: DOR, assessed by BICR and the Investigator
DOR, the time from the first documentation of objective response (CR, PR, or MR) to the date of the first documentation of disease progression RANO 2.0, or death (by any cause in the absence of progression), for participants with confirmed objective response, as assessed by the BICR and the Investigator.
Time frame: from randomization until the date of first documented disease progression, average 2 years
Part2: Time to Response (TTR) assessed by BICR and by the Investigator
TTR, defined as the time from randomization to the first documentation of objective response (CR, PR, or MR) per RANO 2.0, for participants with confirmed objective response, as assessed by the BICR and the Investigator.
Time frame: From randomization until the date of first documented objective response, average 2 years
Part2: Health-related quality of life
The Functional Assessment of Cancer Therapy-Brain (FACT-Br) questionnaire
Time frame: From the first dose of study drug to treatment discontinuation, average 2 years
Part2: Safety and tolerability
AEs graded by NCI CTCAE v5.0, laboratory abnormalities as graded by NCI CTCAE v5.0, vital signs, physical examinations, and ECGs.
Time frame: from the first dose of study drug until 30 days after treatment discontinuation, average 2 years
Part2: Seizure Activity
Defined as seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications.
Time frame: from the first dose of study drug until the date of first documented disease progression, average 2 years
Part2: Safusidenib PK Profile
Defined as safusidenib concentrations and PK parameters.
Time frame: from the first dose of study drug through 20 weeks
Part 3: ORR, assessed by the Investigator
ORR, defined as the proportion of participants with the confirmed best overall response of CR, PR, or MR per RANO 2.0, as assessed by the Investigator.
Time frame: From first dose of study drug until the date of first documented disease progression, average 18 months
Part 3: DOR, assessed by BICR and the Investigator
DOR, the time from the first documentation of objective response (CR, PR, or MR) to the date of the first documentation of disease progression per RANO 2.0, or death (by any cause in the absence of progression), as assessed by the BICR and the Investigator.
Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Part 3: Time to Next Intervention (TTNI)
TTNI, defined as the time from the first dose of study drug to initiation of the first subsequent anticancer therapy.
Time frame: From the first dose of study drug until the date of next treatment, average 18 months
Part 3: PFS assessed by BICR and the Investigator.
PFS, defined as the time from the first dose of study drug to the date of the first documented disease progression per RANO 2.0, or death (by any cause in the absence of disease progression), as assessed by BICR and the Investigator.
Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Part 3: DCR assessed by BICR and by the Investigator
DCR, defined as the proportion of participants with a best overall response of CR, PR, MR, or SD per RANO 2.0, as assessed by the Investigator and BICR
Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Part 3: Time to Response (TTR) assessed by BICR and by the Investigator
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per RANO 2.0, as assessed by the BICR and the Investigator.
Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Part 3: Overall Survival (OS)
OS, defined as the time from the first dose of study drug to death from any cause.
Time frame: From the first dose of study drug until the date of death, average 7 years
Part 3: Safety and tolerability
AEs graded by NCI CTCAE v5.0, laboratory abnormalities as graded by NCI CTCAE v5.0, vital signs, physical examinations, and ECGs.
Time frame: From the first dose of study drug until 30 days after treatment discontinuation, average 18 months
Part 3: Safusidenib PK Profile
Defined as safusidenib concentrations and PK parameters.\[Time Frame: from the first dose of study drug through 20 weeks\]
Time frame: From the first dose of study drug through 20 weeks
Part 3: Health-related quality of life
The Functional Assessment of Cancer Therapy-Brain (FACT-Br) and the Quality of Life in Epilepsy (QOLIE-10-P) questionnaires.
Time frame: From the first dose of study drug to treatment discontinuation, average 18 months
Part 3: Seizure Activity
Defined as seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications.
Time frame: From the first dose of study drug until the date of first documented disease progression, average 18 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Dec 2028, 65 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Safusidenib